The aim of this study was to assess the effect of antiretroviral therapy (ART) versus HIV on mitochondria in fat.
Methods
Subcutaneous fat was collected from 45 HIV-infected patients on ART with lipoatrophy, 11 HIV-infected ART-naive patients and nine healthy controls. Three mitochondrial transcripts: NADH dehydrogenase subunit 1 (ND1), cytochrome B (CYTB) and NADH dehydrogenase subunit 6 (ND6) genes were quantitated using TaqMan® probes and normalized to nuclear-encoded ribosomal L13.
Results
ND1/L13 and CYTB/L13 were lower in HIV-positive patients on ART with lipoatrophy versus ART-naive patients (3.4 versus 7.2 [P=0.017] and 2.5 versus 4.6 [P=0.006], respectively). No difference was found between ART-naive patients and controls (P>0.70). ND6/ L13 was similar between all groups. Dual-energy X-ray absorptiometry-measured limb fat and mitochondrial DNA in fat were also lower in HIV-positive patients on ART with lipoatrophy versus HIV-infected, ART-naive patients (4,382 versus 7,662 g [P=0.02] and 726 versus 1,372 copies/cell [P=0.03], respectively), but no difference was found between ART-naive and controls. In a multiple regression analysis, limb fat correlated with all three mitochrondrial RNA, whereas mitochondrial DNA did not correlate with mitochondrial RNA or limb fat.
Conclusions
In contrast to ART-naive patients, HIV-positive patients on ART with lipoatrophy had significant depletion in mitochondrial DNA in fat and mitochondrial RNAs. This suggests that mitochondrial toxicity in lipoatrophy could be driven by ART and not by HIV itself. In addition, mitochondrial RNA abnormalities, and not mitochondrial DNA depletion, could be a key driving force behind lipoatrophy.
References
1.
WalkerU.A., BickelM., Lμtke VolksbeckS.I.Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients.J Acquir Immune Defic Syndr2002; 29: 117–121.
2.
NolanD., HammondE., MartinA.Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy.AIDS2003; 17: 1329–1338.
3.
McComseyG.A., PaulsenD.M., LonerganT.J.Improvements in lipoatrophy, mitochondrial DNA content and adipose tissue apoptosis levels after replacement of stavudine with either abacavir or zidovudine.AIDS2005; 19: 15–23.
4.
GerschensonM., ShiramizuB., LiButtiD.E., ShikumaC.M.Mitochondrial DNA levels of peripheral blood mononuclear cells and subcutaneous adipose tissue from thigh, fat and abdomen of HIV-1 seropositive and negative individuals.Antivir Ther2005; 10Suppl 2: M83–M89.
5.
DeniaudA., BrennerC., KroemerG.Mitochondrial membrane permeabilization by HIV-1 Vpr.Mitochondrion2004; 4: 223–233.
6.
SabbahE.N., DruillennecS., MorelletN., BouazizS., KroemerG., RoquesB.P.Interaction between the HIV-1 protein Vpr and the adenine nucleotide translocator.Chem Biol Drug Des2006; 67: 145–154.
7.
NieZ., BrenG.D., VlahakisS.R.Human immunodeficiency virus type 1 protease cleaves procaspase 8 in vivo.J Virol2007; 81: 6947–6956.
8.
KotlerD.P., IonescuG., JohnsonJ.A.Studies of adipose tissue metabolism in human immunodeficiency virus-associated lipodystrophy.Clin Infect Dis2003; 37Suppl 2: S47–S51.
9.
GrunfeldC., TienP.Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome.Clin Infect Dis2003; 37Suppl 2: S43–S46.
10.
KotlerD.P., RosenbaumK., WangJ., PiersonR.N.Studies of body composition and fat distribution in HIV-infected and control subjects.J Acquir Immune Defic Syndr Hum Retrovirol1999; 20: 228–237.
11.
Van der ValkM., GisolfE.H., ReissP. and the Prometheus study group. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.AIDS2001; 15: 847–555.
12.
LichtensteinK.A.Redefining lipodystrophy syndrome: risks and impact on clinical decision making.J Acquir Immune Defic Syndr2005; 39: 395–400.
13.
MatthewsD.R., HoskerJ.P., RudenskiA.S.Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man.Diabetologia1985; 28: 412–419.
14.
ShiramizuB., ShikumaK.M., KamemotoL.Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy.J Acquir Immune Defic Syndr2003; 32: 370–374.
15.
CossarizzaA., PintiM., MorettiL.Mitochondrial functionality and mitochondrial DNA content in lymphocytes of vertically infected human immunodeficiency virus-positive children with highly active antiretroviral therapy-related lipodystrophy.J Infect Dis2002; 185: 299–305.
16.
GalluzziL., PintiM., GuaraldiG.Altered mitochondrial RNA production in adipocytes from HIV-infected individuals with lipodystrophy.Antivir Ther2005; 10Suppl 2: M91–M99.
17.
GalluzziL., PintiM., TroianoL.Changes in mitochondrial RNA production in cells treated with nucleoside analogues.Antivir Ther2005; 10: 191–195.
18.
KimM.J., JardelC., BarthélémyC.Mitochondrial DNA content: an inaccurate biomarker of mitochondrial 1 alteration in HIV-related lipodystrophy.Antimicrob Agents Chemother2008; 52: 1670–1676.
19.
d'AmatiG., LewisW.Zidovudine causes early increases in mitochondrial ribonucleic acid abundance and induces ultrastructural changes in cultured mouse muscle cells.Lab Invest1994; 71: 879–884.
20.
MallonP.W., UnemoriP., SedwellR.In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA.J Infect Dis2005; 191: 1686–1696.
21.
ToshiyukiM., MiekoG., NoriakiH.Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy.J Med Virol2003; 70: 497–505.
22.
de MendozaC., de RondeA., SmoldersK.Changes in mitochondrial DNA copy number in blood cells from HIV-infected patients undergoing antiretroviral therapy.AIDS Res Hum Retroviruses2004; 20: 271–273.
23.
BarazzoniR., ShortK.R., NairK.S.Effects of aging on mitochondrial DNA copy number and cytochrome c oxidase gene expression in rat skeletal muscle, liver, and heart.J Biol Chem2000; 275: 3343–3347.
24.
RitovV.B., MenshikovaE.V., HeJ., FerrellR.E., GoodpasterB.H., KelleyD.E.Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes.Diabetes2005; 54: 8–14.
25.
McComseyG.A., WalkerU.A.Mitochondria and HIV lipoatrophy.Mitochondrion2004; 4: 111–118.
26.
LundK.C., PetersonL.L., WallaceK.B.Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs.Antimicrob Agents Chemother2007; 51: 2531–2539.
27.
BarretB., TardieuM., RustinP.Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort.AIDS2003; 17: 1769–1785.
28.
LopezS., MiroO., MartinezE.Mitochondrial effects of antiretroviral therapies in asymptomatic patients.Antivir Ther2004; 9: 47–55.
29.
MiroO., LopezS., Rodriguez de la ConcepcionM.Upregulatory mechanisms compensate for mitochondrial DNA depletion in asymptomatic individuals receiving stavudine plus didanosine.J Acquir Immune Defic Syndr2004; 37: 1550–1555.
30.
McComseyG., BaiR., MaaJ-F, SeekinsD., WongL-J. Extensive investigations of mitochondrial DNA genome in lipoatrophy: beyond mtDNA depletion.J Acquir Immune Defic Syndr2005; 39: 181–188.
31.
SluseF.E., JarmuszkiewiczW., NavetR., DouetteP., MathyG., Sluse-GoffartC.M.Mitochondrial UCPs: new insights into regulation and impact.Biochim Biophys Acta2006; 1757: 480–485.
32.
PetersenK.F., DufourS., BefroyD., GarciaR., ShulmanG.I.Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes.N Engl J Med2004; 350: 664–671.
33.
Study InvestigatorsF.R.A.M.. Fat distribution in men with HIV infection.J Acquir Immune Defic Syndr2005; 40: 121–131.
34.
From the Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM).Fat distribution in women with HIV infection.J Acquir Immune Defic Syndr2006; 42: 562–571.
